SANOFISanofi India Ltd.

    Sanofi India GST show cause notice dropped after ₹17,680 payment

    • Legal
    • Pharmaceuticals

    Sanofi India (NSE: SANOFI) has had a GST show cause notice dropped after paying ₹17,680 in tax and interest on certain blocked credit items, it said in a filing on 17 Nov 2026. The notice had proposed a tax liability of ₹23.74 crore. The company says there is no material impact on its financial, operational or other activities.

    Key highlights

    • Amount paid to conclude proceedings: ₹17,680 (tax ₹10,128, interest ₹7,552)
    • Tax liability proposed in the notice: ₹23.74 crore
    • Adjudication order dated 16 Nov 2026, received the same day
    • Show cause notice dated 25 Sep 2026

    The order in numbers

    ItemDetail
    AuthorityCommercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru
    OrderAdjudication Order dated 16 Nov 2026 under Section 73 of the Karnataka Goods and Services Tax Act, 2017
    Show cause noticeDated 25 Sep 2026, alleging excess Input Tax Credit for April 2022 to March 2023
    Tax liability proposed₹23.74 crore
    Tax paid (CGST and SGST)₹10,128
    Interest paid₹7,552
    Total paid₹17,680
    Further amount payableNone, according to the order
    Company's view of impactNo material impact on financial, operational or other activities

    What the order covers

    The show cause notice was issued by the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, on 25 Sep 2026. It alleged that Sanofi India availed excess Input Tax Credit for April 2022 to March 2023 and proposed to determine a tax liability of ₹23.74 crore. The company intimated the notice to the exchanges on the same day.

    The adjudication order dated 16 Nov 2026, issued under Section 73 of the Karnataka Goods and Services Tax Act, 2017, concluded the proceedings on payment of CGST and SGST of ₹10,128 and interest of ₹7,552, together ₹17,680, relating to certain blocked credit items. The company received the order on 16 Nov 2026. The order says no further amount is payable by the company and that the show cause notice is hereby dropped.

    Payment against the proposed liability

    The amount paid under the order is ₹17,680, against the ₹23.74 crore proposed in the notice. The proposed figure is about 4.8% of the company's standalone total income for Q2 FY27 of ₹497.20 crore, according to Blacklitt's data.

    The order ties the payment to blocked credit items, while the notice's allegation covered excess credit claimed across April 2022 to March 2023. The order's wording is that no further amount is payable and the notice is dropped, so the matter is closed on the order's own terms.

    What the GST order means for Sanofi India's shareholders

    The order closes this GST matter with a payment of ₹17,680, and the company says it has no material impact on its financial, operational or other activities. The order records the notice as dropped, with no further amount payable by the company.

    Not stated in the filing: why the input tax credit was treated as excess, the company's own position on the allegation beyond its submissions, whether it will appeal or take further action, and whether any other amount was paid in respect of the notice. The filing sets no further dated step.

    Filed with NSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Sanofi India Ltd. articles